Posts Tagged ‘GR-II’
December Will Be Exciting for Up and Coming Corcept Pharmaceuticals

In December, the Phase 3 results for Corlux for the treatment of Cushing’s Syndrome are due out and investors have been showing an appetite for the stock as of late.

Read more ...